Iloprost Zentiva (Iloprost)

Iloprost selectively binds to the IP (prostacyclin) receptor on vascular smooth‑muscle cells, increasing intracellular cyclic AMP. This leads to potent vasodilation of pulmonary arteries, inhibition of platelet aggregation, and antiproliferative effects on vascular remodeling, which together improve hemodynamics in pulmonary arterial hypertension and support tissue repair in digital ulcers.

The prescribed dose of Iloprost Zentiva is individualized by the treating physician based on disease severity, patient tolerance, and response to therapy. Dosing regimens typically involve multiple inhalations per day using a nebulizer, but the exact schedule and concentration are determined by the prescriber and should not be altered without medical guidance.

The safety of Iloprost during pregnancy and lactation has not been definitively established. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To order Iloprost Zentiva, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and assist with import documentation.

Iloprost belongs to the prostacyclin analog class, similar to epoprostenol and treprostinil. Compared with epoprostenol, Iloprost is administered via inhalation, offering targeted pulmonary delivery and a lower systemic side‑effect profile. Treprostinil can be delivered subcutaneously, intravenously, or by inhalation; Iloprost’s inhaled route provides rapid onset with fewer infusion‑related complications.

Iloprost Zentiva should be stored at room temperature, below 25 °C, in its original packaging. Protect the solution from direct light, moisture, and extreme temperatures. Keep the vial tightly sealed when not in use and discard any solution that appears discolored or cloudy.

Iloprost Zentiva is administered by inhalation using a compatible nebulizer system. The patient inhales the prescribed dose through a mouthpiece or mask, typically multiple times per day as directed by the prescriber. Proper device cleaning and maintenance are essential to ensure accurate dosing and prevent contamination.

Serious risks include pulmonary edema, severe hypotension, significant bleeding due to platelet inhibition, thrombocytopenia, and rare allergic reactions such as anaphylaxis. Patients should be instructed to seek immediate medical attention if they experience sudden shortness of breath, fainting, uncontrolled bleeding, or signs of an allergic reaction.

Iloprost Zentiva is contraindicated in patients with severe left‑heart disease, uncontrolled systemic hypotension, active bleeding disorders, or known hypersensitivity to iloprost or any component of the formulation. Caution is also advised for individuals with recent myocardial infarction or unstable angina, and it should be avoided in those for whom inhalation therapy is not feasible.